PCSK9 and diabetes mellitus: Long-term safety data on PCSK9 inhibitors are not available given the limited follow up of clinical trials that have been conducted so far.35 In particular, there is a theoretical concern for increased risk of diabetes, neurocognitive disorders, and cataracts.